Literature DB >> 18762760

Unrelated cord blood and mismatched unrelated volunteer donor transplants, two alternatives in patients who lack an HLA-identical donor.

O Ringdén1, M Okas, M Uhlin, M Uzunel, M Remberger, J Mattsson.   

Abstract

The aim was to evaluate two transplant strategies for patients who lack HLA-identical donors, namely HLA-A, HLA-B or -DR beta 1 mismatched unrelated donor (MM URD) transplants (n=14) and umbilical cord blood transplants (UCB, n=27). Diagnosis, disease stage and age were similar in the two groups. Cell dose was lower in the UCB group (P<0.001). Median time to ANC of >0.5 x 10(9)/l was 30 days in the UCB group and 17 days in the MM URD group (P=0.002). Engraftment of plt was delayed in the UCB group (P=0.03). The UCB patients required fewer erythrocyte transfusions (P=0.001). At 100 days, complete donor chimerism for CD3 was 63 and 44% in the UCB and MM URD groups, respectively. Acute GVHD of grades II-IV were 30% in the UCB group and 21% in the MM URD group. The corresponding figures for chronic GVHD were 9 and 20%, respectively. TRM was 30% in the UCB patients and 50% in the MM URD patients. Three-year survival was 66% in the UCB group and 14% in the MM URD group (P=0.006). Although the material is small and heterogeneous, engraftment was delayed, leukocyte chimerism was not significantly different and survival was superior using UCB rather than MM URD transplants.

Entities:  

Mesh:

Year:  2008        PMID: 18762760     DOI: 10.1038/bmt.2008.239

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  Stable mixed double donor chimerism: Absence of war doesn't necessarily mean peace.

Authors:  Jens Gertow; Jonas Mattsson J; Michael Uhlin
Journal:  Chimerism       Date:  2010-10

2.  Characterization of long-term mixed donor-donor chimerism after double cord blood transplantation.

Authors:  J Gertow; S Berglund; M Okas; M Uzunel; L Berg; K Kärre; J Mattsson; M Uhlin
Journal:  Clin Exp Immunol       Date:  2010-08-20       Impact factor: 4.330

3.  Stable mixed donor-donor chimerism after double cord blood transplantation.

Authors:  Sofia Berglund; Mantas Okas; Jens Gertow; Michael Uhlin; Jonas Mattsson
Journal:  Int J Hematol       Date:  2009-08-22       Impact factor: 2.490

4.  Alpha/beta T-cell depleted grafts as an immunological booster to treat graft failure after hematopoietic stem cell transplantation with HLA-matched related and unrelated donors.

Authors:  E Rådestad; H Wikell; M Engström; E Watz; B Sundberg; S Thunberg; M Uzunel; J Mattsson; M Uhlin
Journal:  J Immunol Res       Date:  2014-10-13       Impact factor: 4.818

5.  Stem cell transplantation during cancer.

Authors:  Xiao-Ying Zhang; Pei-Ying Zhang
Journal:  Oncol Lett       Date:  2016-10-13       Impact factor: 2.967

6.  Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis.

Authors:  Arjang Baygan; Wictor Aronsson-Kurttila; Gianluca Moretti; Babylonia Tibert; Göran Dahllöf; Lena Klingspor; Britt Gustafsson; Bita Khoein; Guido Moll; Charlotta Hausmann; Britt-Marie Svahn; Magnus Westgren; Mats Remberger; Behnam Sadeghi; Olle Ringden
Journal:  Front Immunol       Date:  2017-07-11       Impact factor: 7.561

7.  Intraarterial transplantation of human umbilical cord blood mononuclear cells is more efficacious and safer compared with umbilical cord mesenchymal stromal cells in a rodent stroke model.

Authors:  Neha Karlupia; Nathan C Manley; Kameshwar Prasad; Richard Schäfer; Gary K Steinberg
Journal:  Stem Cell Res Ther       Date:  2014-04-01       Impact factor: 6.832

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.